274676-47-0

Basic information

• Product Name: 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI)
• Synonyms: 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI);1,2,3,4-tetrahydro-7-Methyl-1,8-Naphthyridine;1,8-Naphthyridine, 1,2,3,4-tetrahydro-7-methyl-
• CAS NO: 274676-47-0
• Molecular Formula: C₉H₁₂N₂
• Molecular Weight: 148.208
• Product Categories: PYRIDINE
• Mol File: 274676-47-0.mol
• Article Data: 15

Chemical Properties

• Melting Point: 88-91℃
• Boiling Point: 334.1±15.0 °C(Predicted)
• Appearance: /
• Density: 1.15±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C(protect from light)
• PKA: 10.83±0.40(Predicted)
• CAS DataBase Reference: 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI)(274676-47-0)
• EPA Substance Registry System: 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI)(274676-47-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 274676-47-0(Hazardous Substances Data)

Usage

General Description

1,8-Naphthyridine, 1,2,3,4-tetrahydro-7-methyl-(9CI) is a chemical compound that belongs to the class of naphthyridine derivatives. It is a heterocyclic compound with a fused ring system containing both nitrogen and carbon atoms. 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI) has a molecular formula of C11H13N and a molecular weight of 159.23 g/mol. The chemical structure of 1,8-Naphthyridine, 1,2,3,4-tetrahydro-7-methyl-(9CI) consists of a methyl group attached to the 7th carbon atom of the tetrahydro-1,8-naphthyridine ring. 1,8-Naphthyridine,1,2,3,4-tetrahydro-7-methyl-(9CI) may have potential applications in the pharmaceutical industry due to its unique structure and potential biological activities.

Upstream product

• 1569-16-0 2-methyl-[1,8]naphthyridine 
• 504-29-0 2-aminopyridine 
• 7521-41-7 2-Aminonicotinaldehyde 
• 76293-30-6 N-tert-butyl-2-aminopyridine 
• 855313-30-3 2-tert-butylamino-pyridine-3-carbaldehyde 
• 885276-99-3 2-amino-6-methylpyridine-3-carbaldehyde 
• 67-64-1 acetone 
• 1824-81-3 2-Amino-6-methylpyridine 
• 55469-90-4 7-methyl-2,3-dihydro-1,8-naphthyridin-4-(1H)one 
• 55469-89-1 N-(6-methyl-[2]pyridyl)-β-alanine 
• 1292955-81-7 C₉H₁₂N₂O 
• 1292237-99-0 ethyl 3-[(6-methylpyridine-2-yl)amino]propionate 
• 23612-57-9 (2-amino-3-pyridinyl)methanol 
• 67-63-0 isopropyl alcohol 

Downstream Products

• 243641-37-4 tert-butyl 7-methyl-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxylate 
• 445492-19-3 (8-N-Boc-5,6,7,8-tetrahydro[1,8]naphthyridin-2-yl)acetic acid 
• 445490-79-9 7-[2-(3-methyl-4-nitro-phenoxy)-ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 855313-35-8 7-[1,1-difluoro-2-(3-methyl-4-nitro-phenoxy)-ethyl]-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 
• 445489-88-3 3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid 
• 445490-83-5 3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-32-7 3-(3-chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-20-3 3-(2-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-23-6 3-(3-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-26-9 3-(4-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445491-06-5 3-biphenyl-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid ethyl ester 
• 445490-82-4 7-{2-[1-(2-ethoxycarbonyl-1-phenyl-ethyl)-1H-indol-5-yloxy]-ethyl}-3,4-dihydro-2H-[1,8]naphthyridine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Pyrrolidine integrin regulator and application thereof

Disclosed are a compound as represented by formula I, and a racemate, a stereoisomer, a tautomer, an isotopic marker, a nitrogen oxide, a solvate, a polymorph, a metabolite, an ester, and a prodrug thereof or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising same, a preparation method therefor, and the medical use thereof. The structure of formula I is as follows:

INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION

Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: (I)

2,6-DIAMINOPYRIDINE COMPOUNDS SUITABLE FOR TREATING DISEASES ASSOCIATED WITH AMYLOID OR AMYLOID-LIKE PROTEINS OR FOR TREATING OR PREVENTING OCULAR DISEASES OR CONDITIONS ASSOCIATED WITH A PATHOLOGICAL ABNORMALITY/CHANGE IN THE TISSUE OF THE VISUAL SYSTEM

The present invention relates to 2.6-diaminopyridine compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein and of diseases or conditions associated with amyloid-like proteins. The compoun